HUP0202450A2 - N-heterociklusos származékok mint NOS inhibitorok - Google Patents

N-heterociklusos származékok mint NOS inhibitorok

Info

Publication number
HUP0202450A2
HUP0202450A2 HU0202450A HUP0202450A HUP0202450A2 HU P0202450 A2 HUP0202450 A2 HU P0202450A2 HU 0202450 A HU0202450 A HU 0202450A HU P0202450 A HUP0202450 A HU P0202450A HU P0202450 A2 HUP0202450 A2 HU P0202450A2
Authority
HU
Hungary
Prior art keywords
group
alkyl
compounds
atom
hydrogen atom
Prior art date
Application number
HU0202450A
Other languages
English (en)
Inventor
Damian O. Arnaiz
John J. Baldwin
David D. Davey
James J. Devlin
Roland Ellwood Dolle Iii
Shawn David Erickson
Kirk Mcmillan
Michael M. Morrissey
Michael H. J. Ohlmeyer
Gonghua Pan
Vidyadhar Madhav Paradkar
John Parkinson
Gary B. Phillips
Bin Ye
Zuchun Zhao
Original Assignee
Berlex Laboratories, Inc.
Pharmacopeia, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Berlex Laboratories, Inc., Pharmacopeia, Inc. filed Critical Berlex Laboratories, Inc.
Publication of HUP0202450A2 publication Critical patent/HUP0202450A2/hu
Publication of HUP0202450A3 publication Critical patent/HUP0202450A3/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles

Abstract

A találmány tárgya (Ya), (Yb) vagy (Yc) általános képletű N-heterociklusos vegyületek, továbbá további N-heterociklusok, amelyek anitrogénoxid-szintáz inhibitorának alkalmasak. Ezeket a vegyületekettartalmazó farmakológiai kompozíciókat, a vegyületek nitrogénoxid-szintáz inhibitoraként történő alkalmazásának módszereit és avegyületek szintetizálásának módszereit is ismertetik. n és mmindegyike 1-tőt 4-ig terjedő egész szám; A egy -C(O)OR1 vagy -C(O)ON(R1)R2 csoportot jelent; W mindegyike N-atomot vagy CH-csoportot jelent; R1 mindegyikeegymástól függetlenül hidrogénatom, alkil-, aril- vagy aralkilcsoport;R2 mindegyike egymástól függetlenül hidrogénatom, 0-20 szénatomosalkil-, -(CH2)n-N(R1)2, heterociklilalkil- (amely opcionálisanhelyettesítve lehet alkilcsoporttal, halogénatommal, halogénalkil-vagy alkoxicsoporttal), aralkilcsoport (amely opcionálisanhelyettesítve lehet halogénatommal, alkil-, alkoxi- vagy -N(R1)2csoporttal); R4 hidroxi-, ciano-, heterociklil-, -N(R1)R2, -N(R1)-C(O)-R1, -N(R1)-C(O)OR1, -N(R1)-S(O)t-R1, vagy -N(R1)-C(O)-N(R1)2-csoport; R5 hidrogénatom, halogénatom, alkil-, aril-, aralkil-, vagyhalogénezett alkilcsoport. Ó
HU0202450A 1999-08-26 2000-08-24 N-heterocyclic derivatives as nos inhibitors HUP0202450A3 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US09/383,813 US6432947B1 (en) 1997-02-19 1999-08-26 N-heterocyclic derivatives as NOS inhibitors

Publications (2)

Publication Number Publication Date
HUP0202450A2 true HUP0202450A2 (hu) 2002-11-28
HUP0202450A3 HUP0202450A3 (en) 2003-12-29

Family

ID=23514822

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0202450A HUP0202450A3 (en) 1999-08-26 2000-08-24 N-heterocyclic derivatives as nos inhibitors

Country Status (34)

Country Link
US (11) US6432947B1 (hu)
EP (1) EP1206467B1 (hu)
JP (1) JP4739625B2 (hu)
KR (1) KR100708783B1 (hu)
CN (1) CN1206228C (hu)
AT (1) ATE256681T1 (hu)
AU (1) AU769405B2 (hu)
BG (1) BG65804B1 (hu)
BR (1) BR0014144A (hu)
CA (1) CA2376355C (hu)
CZ (1) CZ2002642A3 (hu)
DE (1) DE60007329T2 (hu)
DK (1) DK1206467T3 (hu)
EE (1) EE05199B1 (hu)
ES (1) ES2213599T3 (hu)
HK (2) HK1043594A1 (hu)
HR (1) HRP20020175B1 (hu)
HU (1) HUP0202450A3 (hu)
IL (2) IL148313A0 (hu)
LT (1) LT4982B (hu)
LV (1) LV12887B (hu)
MX (1) MXPA02002022A (hu)
NO (1) NO323886B1 (hu)
NZ (1) NZ517411A (hu)
PL (1) PL353539A1 (hu)
PT (1) PT1206467E (hu)
RO (1) RO122202B1 (hu)
RS (1) RS50378B (hu)
RU (1) RU2277094C2 (hu)
SI (1) SI20818B (hu)
SK (1) SK2622002A3 (hu)
UA (1) UA72930C2 (hu)
WO (1) WO2001014371A1 (hu)
ZA (1) ZA200201485B (hu)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6432947B1 (en) * 1997-02-19 2002-08-13 Berlex Laboratories, Inc. N-heterocyclic derivatives as NOS inhibitors
HRP990246A2 (en) * 1998-08-07 2000-06-30 Du Pont Pharm Co Succinoylamino benzodiazepines as inhibitors of a beta protein production
NZ525513A (en) 1998-08-07 2004-09-24 Pont Pharmaceuticals Du Succinoylamino lactams as inhibitors of Abeta protein production
AU777735B2 (en) * 1999-07-15 2004-10-28 Pharmacopeia, Inc. Bradykinin B1 receptor antagonists
GB2361473C (en) * 2000-03-08 2005-06-28 Microgenics Corp Ecstasy-class analogs and use of same in detection of ecstasy-class compounds
EP1268433A1 (en) 2000-04-03 2003-01-02 Bristol-Myers Squibb Pharma Company Cyclic lactams as inhibitors of a-beta-protein production
US20030055249A1 (en) * 2001-07-17 2003-03-20 Fick David B. Synthesis and methods of use of pyrimidine analogues and derivatives
US8571653B2 (en) * 2001-08-31 2013-10-29 Bio Control Medical (B.C.M.) Ltd. Nerve stimulation techniques
US7885709B2 (en) * 2001-08-31 2011-02-08 Bio Control Medical (B.C.M.) Ltd. Nerve stimulation for treating disorders
US7778711B2 (en) * 2001-08-31 2010-08-17 Bio Control Medical (B.C.M.) Ltd. Reduction of heart rate variability by parasympathetic stimulation
US7904176B2 (en) 2006-09-07 2011-03-08 Bio Control Medical (B.C.M.) Ltd. Techniques for reducing pain associated with nerve stimulation
EP1795192A3 (en) * 2002-04-30 2008-05-07 Bayer Schering Pharma Aktiengesellschaft 1-(Pyridazin-3-yl)-imidazole derivatives as inhibitors of nitric oxide synthase (NOS)
US6982259B2 (en) * 2002-04-30 2006-01-03 Schering Aktiengesellschaft N-heterocyclic derivatives as NOS inhibitors
WO2004019986A1 (en) * 2002-08-29 2004-03-11 Schering Aktiengesellschaft Methods of treating acute respiratory distress syndrome
US20040077650A1 (en) * 2002-10-18 2004-04-22 Pfizer Inc. Cannabinoid receptor ligands and uses thereof
EP1716134A4 (en) * 2004-02-12 2007-10-17 Merck & Co Inc AMINO HETEROCYCLIC COMPOUNDS MODULATING CHEMOKINE RECEPTOR ACTIVITY
EP1568698A1 (en) * 2004-02-27 2005-08-31 Aventis Pharma Deutschland GmbH Pyrrole-derivatives as factor Xa inhibitors
CN1960988B (zh) * 2004-06-10 2012-01-25 Irm责任有限公司 作为蛋白激酶抑制剂的化合物和组合物
KR100935273B1 (ko) * 2004-06-10 2010-01-06 아이알엠 엘엘씨 단백질 키나제 억제제 화합물 및 조성물
EP1796673A2 (en) * 2004-09-23 2007-06-20 Reddy US Therapeutics, Inc. Novel pyrimidine compounds, process for their preparation and compositions containing them
UY29177A1 (es) * 2004-10-25 2006-05-31 Astex Therapeutics Ltd Derivados sustituidos de purina, purinona y deazapurina, composiciones que los contienen métodos para su preparación y sus usos
MY179032A (en) * 2004-10-25 2020-10-26 Cancer Research Tech Ltd Ortho-condensed pyridine and pyrimidine derivatives (e.g.purines) as protein kinase inhibitors
WO2006055831A2 (en) * 2004-11-17 2006-05-26 Miikana Therapeutics, Inc. Kinase inhibitors
JP2008521908A (ja) * 2004-12-01 2008-06-26 カリプシス・インコーポレーテッド 誘導型一酸化窒素シンターゼ阻害剤
US20070123572A1 (en) * 2005-11-28 2007-05-31 Kalypsys, Inc. Novel method of preparation of 5-chloro-3-imidazol-1-yl-[1,2,4]thiadiazole and (3-imidazol-1-yl-[1,2,4]thiadiazol-5yl)-dialkyl-amines
KR101155335B1 (ko) * 2005-01-07 2012-06-11 엘지전자 주식회사 이동통신 단말기의 멀티미디어 메시지 동작방법
US7884109B2 (en) * 2005-04-05 2011-02-08 Wyeth Llc Purine and imidazopyridine derivatives for immunosuppression
RU2007140903A (ru) * 2005-04-05 2009-05-20 Фармакопия, Инк. (Us) Производные пурина и имидазопиридина для иммуносупрессии
CA2618653A1 (en) 2005-08-12 2007-02-22 Takeda Pharmaceutical Company Limited Brain/neuronal cell-protecting agent and therapeutic agent for sleep disorder
AU2006297120B2 (en) * 2005-09-30 2011-05-19 Miikana Therapeutics, Inc. Substituted pyrazole compounds
CN101454317A (zh) * 2005-11-28 2009-06-10 凯利普西斯公司 作为一氧化氮合酶二聚化抑制剂的咪唑衍生物
US7989459B2 (en) * 2006-02-17 2011-08-02 Pharmacopeia, Llc Purinones and 1H-imidazopyridinones as PKC-theta inhibitors
US20090281075A1 (en) * 2006-02-17 2009-11-12 Pharmacopeia, Inc. Isomeric purinones and 1h-imidazopyridinones as pkc-theta inhibitors
US8017612B2 (en) * 2006-04-18 2011-09-13 Japan Tobacco Inc. Piperazine compound and use thereof as a HCV polymerase inhibitor
EP2013206A1 (en) * 2006-04-25 2009-01-14 Astex Therapeutics Limited Pharmaceutical compounds
US8796293B2 (en) * 2006-04-25 2014-08-05 Astex Therapeutics Limited Purine and deazapurine derivatives as pharmaceutical compounds
EP3146982B1 (en) 2006-10-03 2019-08-21 Genzyme Corporation Gene therapy for amyotrophic lateral sclerosis and other spinal cord disorders
WO2008043019A1 (en) * 2006-10-04 2008-04-10 Pharmacopeia, Inc 8-substituted 2-(benzimidazolyl) purine derivatives for immunosuppression
US7902187B2 (en) * 2006-10-04 2011-03-08 Wyeth Llc 6-substituted 2-(benzimidazolyl)purine and purinone derivatives for immunosuppression
US7919490B2 (en) * 2006-10-04 2011-04-05 Wyeth Llc 6-substituted 2-(benzimidazolyl)purine and purinone derivatives for immunosuppression
US20080119496A1 (en) * 2006-11-16 2008-05-22 Pharmacopeia Drug Discovery, Inc. 7-Substituted Purine Derivatives for Immunosuppression
EP1939181A1 (en) * 2006-12-27 2008-07-02 sanofi-aventis Heteroaryl-substituted carboxamides and use thereof for the stimulation of the expression of NO synthase
AU2008262291A1 (en) * 2007-06-11 2008-12-18 Miikana Therapeutics, Inc. Substituted pyrazole compounds
KR101494734B1 (ko) * 2007-10-11 2015-02-26 아스트라제네카 아베 단백질 키나제 ｂ 억제제로서 피롤로[2,3-ｄ]피리미딘 유도체
WO2009097474A1 (en) * 2008-01-30 2009-08-06 Smithkline Beecham Corporation Novel seh inhibitors and their use
JP2011510998A (ja) * 2008-01-30 2011-04-07 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー 新規ｓＥＨ阻害剤およびその使用
JP2011510997A (ja) * 2008-01-30 2011-04-07 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー 新規ｓＥＨ阻害剤およびその使用
US20110053907A1 (en) * 2008-03-27 2011-03-03 Auckland Uniservices Limited Substituted pyrimidines and triazines and their use in cancer therapy
GB0908394D0 (en) 2009-05-15 2009-06-24 Univ Leuven Kath Novel viral replication inhibitors
GB0913636D0 (en) 2009-08-05 2009-09-16 Univ Leuven Kath Novel viral replication inhibitors
EP2477826B1 (en) 2009-09-18 2016-06-01 Volvo Lastvagnar AB Console for attachment to a vehicle chassis and vehicle comprising a suspension carrying console
AU2011331301A1 (en) 2010-11-15 2013-05-23 Katholieke Universiteit Leuven Antiviral condensed heterocyclic compounds
CN102617503B (zh) * 2011-03-03 2014-05-07 上海常丰生物医药科技有限公司 (s)-3-吗啉基羧酸的合成方法
EP2694056B1 (en) 2011-04-01 2019-10-16 AstraZeneca AB Therapeutic treatment
LT2785349T (lt) 2011-11-30 2019-12-10 Astrazeneca Ab Kombinuotas vėžio gydymas
AU2013204533B2 (en) 2012-04-17 2017-02-02 Astrazeneca Ab Crystalline forms
EP3166938A4 (en) * 2014-07-11 2018-01-17 Northwestern University 2-imidazolyl-pyrimidine scaffolds as potent and selective inhibitors of neuronal nitric oxide synthase
GB201512635D0 (en) 2015-07-17 2015-08-26 Ucl Business Plc Uses of therapeutic compounds
MX2019007189A (es) 2016-12-20 2019-10-09 Astrazeneca Ab Compuestos de amino-triazolopiridina y su uso en el trataniento del cancer.
CN107115334A (zh) * 2017-03-04 2017-09-01 王宏 一种治疗免疫性流产的药物组合物
WO2019183577A1 (en) 2018-03-23 2019-09-26 Carmot Therapeutics, Inc. Modulators of g-protein coupled receptors

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6339875A (ja) 1986-08-05 1988-02-20 Nissin Food Prod Co Ltd ピリミジン誘導体
DE4118720A1 (de) 1991-06-07 1992-12-10 Bayer Ag Substituierte imidazolinylpyrimidine
TW212798B (hu) * 1991-11-25 1993-09-11 Takeda Pharm Industry Co Ltd
AU665238B2 (en) 1992-02-28 1995-12-21 Zenyaku Kogyo Kabushiki Kaisha S-triazine derivative and remedy for estrogen-dependent diseases containing the same as active ingredient
US5593992A (en) 1993-07-16 1997-01-14 Smithkline Beecham Corporation Compounds
ES2114662T3 (es) 1993-08-26 1998-06-01 Ono Pharmaceutical Co Derivados de la 4-aminopirimidina.
US5426110A (en) 1993-10-06 1995-06-20 Eli Lilly And Company Pyrimidinyl-glutamic acid derivatives
US5629322A (en) 1994-11-15 1997-05-13 Merck & Co., Inc. Cyclic amidine analogs as inhibitors of nitric oxide synthase
AU4149696A (en) 1994-11-15 1996-06-06 Merck & Co., Inc. Substituted heterocycles as inhibitors of nitric oxide synthase
ATE236161T1 (de) * 1995-11-01 2003-04-15 Novartis Pharma Gmbh Purinderivate und verfahren zu ihrer herstellung
ZA977427B (en) 1996-09-04 1998-03-02 Dainippon Pharmaceutical Co 2,4-disubstituted pyrimidine derivative, process for preparing the same, and a pharmaceutical composition containing the same.
DK0968206T3 (da) * 1997-02-19 2007-03-26 Berlex Inc N-heterocykliske derivater som NOS-inhibitorer
US6432947B1 (en) * 1997-02-19 2002-08-13 Berlex Laboratories, Inc. N-heterocyclic derivatives as NOS inhibitors
US6172005B1 (en) * 1997-03-11 2001-01-09 E. I. Du Pont De Nemours And Company Heteroaryl azole herbicides
US6525051B2 (en) 2000-03-27 2003-02-25 Schering Aktiengesellschaft N-heterocyclic derivatives as NOS inhibitors

Also Published As

Publication number Publication date
US6864368B2 (en) 2005-03-08
CA2376355C (en) 2009-10-27
SI20818B (sl) 2009-04-30
EE200200091A (et) 2003-04-15
US20030060452A1 (en) 2003-03-27
PL353539A1 (en) 2003-12-01
BG106440A (en) 2002-11-29
NO323886B1 (no) 2007-07-16
US20020183323A1 (en) 2002-12-05
JP4739625B2 (ja) 2011-08-03
US20030083332A1 (en) 2003-05-01
DE60007329T2 (de) 2004-06-09
US6432947B1 (en) 2002-08-13
UA72930C2 (uk) 2005-05-16
LT2002028A (en) 2002-09-25
CZ2002642A3 (cs) 2002-08-14
PT1206467E (pt) 2004-05-31
US6747031B2 (en) 2004-06-08
BR0014144A (pt) 2002-05-21
KR100708783B1 (ko) 2007-04-19
US6864263B2 (en) 2005-03-08
US20030092678A1 (en) 2003-05-15
CN1206228C (zh) 2005-06-15
ATE256681T1 (de) 2004-01-15
MXPA02002022A (es) 2002-10-31
NO20020925D0 (no) 2002-02-26
DE60007329D1 (de) 2004-01-29
AU7067100A (en) 2001-03-19
EP1206467A1 (en) 2002-05-22
IL148313A0 (en) 2002-09-12
HRP20020175B1 (en) 2008-07-31
YU12002A (sh) 2005-03-15
EP1206467B1 (en) 2003-12-17
ES2213599T3 (es) 2004-09-01
RS50378B (sr) 2009-11-10
HUP0202450A3 (en) 2003-12-29
RO122202B1 (ro) 2009-02-27
JP2003507476A (ja) 2003-02-25
NZ517411A (en) 2003-09-26
NO20020925L (no) 2002-04-16
RU2277094C2 (ru) 2006-05-27
KR20020062277A (ko) 2002-07-25
SK2622002A3 (en) 2002-09-10
US20030078265A1 (en) 2003-04-24
US6846829B2 (en) 2005-01-25
US20030004137A1 (en) 2003-01-02
ZA200201485B (en) 2003-07-30
CN1382136A (zh) 2002-11-27
WO2001014371A1 (en) 2001-03-01
HK1051683A1 (en) 2003-08-15
LV12887B (en) 2003-01-20
US6887865B2 (en) 2005-05-03
LT4982B (lt) 2003-01-27
US6849739B2 (en) 2005-02-01
DK1206467T3 (da) 2004-04-26
US6841673B2 (en) 2005-01-11
EE05199B1 (et) 2009-08-17
HK1043594A1 (zh) 2002-09-20
IL148313A (en) 2008-04-13
US6841674B2 (en) 2005-01-11
SI20818A (sl) 2002-08-31
CA2376355A1 (en) 2001-03-01
HRP20020175A2 (en) 2005-10-31
US20030073669A1 (en) 2003-04-17
US20020165203A1 (en) 2002-11-07
US20030069210A1 (en) 2003-04-10
US6670473B2 (en) 2003-12-30
US20030027794A1 (en) 2003-02-06
AU769405B2 (en) 2004-01-29
BG65804B1 (bg) 2009-12-31

Similar Documents

Publication Publication Date Title
HUP0202450A2 (hu) N-heterociklusos származékok mint NOS inhibitorok
ATE252097T1 (de) N-heterocyclische derivate als nos inhibitoren
DK1392714T3 (da) Steroider som agonister for FXR
DK0968206T3 (da) N-heterocykliske derivater som NOS-inhibitorer
YU57603A (sh) Inhibitori fosfodiesteraze 4
TW200420542A (en) A compound having TGF β inhibition activity and a medicinal composition containing the same
TW200738667A (en) Preparation method for dioxan-2-ylalkylcarbamate derivatives and intermediate thereof
NO972666L (no) Anilinderivater med nitrogenmonoksyd-synteseinhiberende aktivitet
HUP0203288A2 (hu) Foszfodiészteráz VII inhibitor hatású pirrolszármazékok, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk
ATE83773T1 (de) 3(2h)pyridazinon, verfahren zu dessen herstellung und dieses enthaltendes mittel gegen srs-a.
HUP0402235A2 (hu) 4,4-Difluor-1,2,3,4-tetrahidro-5H-1-benzazepin-származékok és ezek sói és ezeket tartalmazó gyógyszerkészítmények
DK0918776T3 (da) Totalsyntese af antitumor acylfulvener
HRP20050082A2 (en) 6-amino-1h-indazole and 4-aminobenzofuran compounds as phosphodiesterase 4 inhibitors
HUP0302193A2 (hu) 1,4-Diazabiciklo[3.2.2]nonán-benzoxazol,-benzotiazol és -benzimidazol-származékok, előállításuk és ezeket tartalmazó gyógyszerkészítmények
HUP0301649A2 (hu) Eljárás [(aza-cikloalkanoil)-amino]-tiazolok előállítására
HUP0004317A2 (hu) 5-HT1F agonisták
DE60000978T2 (de) 22r-hydroxycholesta-8,14-diene derivate zur hemmung der meiose
HUP0302820A2 (hu) CNS rendellenességek kezelésében hasznos indolszármazékok és ezeket tartalmazó gyógyszerkészítmények
HUP0201863A2 (hu) Új morfolinszármazékok, eljárás előállításukra és azokat tartalmazó gyógyszerkészítmények
HUP0203384A2 (hu) Eljárás ketiminek előállítására
TNSN08023A1 (en) Novel polysubstituted 1,1-pyridinyl aminocyclopropanamine derivatives, method for preparing same and pharmaceutical compositions containing same
DE68915484D1 (de) Sulfonylindolizinderivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Synthese-Zwischenprodukte.
DE69303352T2 (de) Verfahren zur Herstellung 5-Pyrazolomerkaptan-Derivate und dessen zwischenprodukte
TH58475B (th) อนุพันธุ์ของ 1,4-ไดอะซาไบไซโคล [3.2.2]โนเนน-4-คาร์บอกซีเลต และ คาร์บอกซามีด การเตรียมและการใช้รักษาโรค

Legal Events

Date Code Title Description
FD9A Lapse of provisional protection due to non-payment of fees